let's hope that's the case. At this price, it seems like the pipeline is valued at about $0, so unless they do, or say something stupid... I would like to know what execs have been doing for the past year to earn their high salaries and stock options rewards. I can't see any notable progress in human clinical trials for some time.
The ASCO conference is coming up at the end of May. I noted (on the IV board) that IMGN will be mentioned in 12 abstracts at the conference. This appears to be progress? You agree?
not impressed, they are all posters and the number of patients treated with the drugs in their internal pipeline is very low, progressing too slow. I thought we would get advanced phase I/II human trial info by early/mid this year on everything but 289, not hearing much about that lately. The competition is moving at light speed, these greedy, do-nothing "execs" doing very little to move the pipeline forward and are destroying value. The BOD must take action to protect the shareholders from DJ and co.
"Kadcyla, the first armed-antibody treatment for breast cancer, was only introduced into the U.K. in February, but according to a recent report, in the first 9 months since its approval in the U.S, it is being prescribed by more than 80% of oncologists. "
This is what I've been hearing as well.
still, we already know the sales for Q1 and Kadcyla revs are based on last quarter, which I think was 70MM, so only about 2.1MM to IMGN. Kadcyla will continue to grow steadily until they get additional approvals, then it will get into the BB's, but that will not ne in 2014. Guessing sales will be about 500-600MM in 2014 then $1BB in 2015 then $2BB in 16 and double again in 17 to $4BB. Roche should buy them no while the shareholders are angry and open to a low bid. Maybe they can get the pipeline moving.
Agree. I'm not expecting too much this quarter. Probably inline with guidance. But I think future quarters look promising. Kadcyla's hurdle is the price ~7500 per month
Wow, i just can't believed it how this site really change my life'....you guys have checked it out! Thank you so much for the recommendation OP
I expect a miss of at least a few $MM on revs and a loss of .30 or higher vs .27 estimate, but that a wild guess. Maybe they will get a small fee for Japan approval for Q2 + $3MM in Kad revs. At $2BB in Kad revs, around 2016 (a guess) IMGN could get close to break even. Maybe management should focus on this since they have nothing to offer on pipeline development results
Roche is putting a lot of sales and marketing muscles behind Kadcyla because they're going to be hurting with Herceptin's patent loss. They're hoping Kadcyla will be their next margin rich product. $2B in 2016 seems about right but it wouldn't surprise me if Roche achieves that sooner.
Phase I and II SAR compounds: not IMGN progress and far away.
Phase I IMGN529: Really? Phase I? I have only been investing for a few years but I remember seeing this drug when I first started and they've only gotten some phase I data?
Toxicity of 853: Defensive, not efficacy, but still good since there's been speculation of toxicity issues in the past. This supports, but doesn't advance technology.
2 studies of Kadcyla and efficacy: good but I'm still wondering where the really money is with this drug. I was under the (false) impression that it would be raking in good money replacing herceptin. Instead I see 100 million in sales for the quarter. That gives IMGN 3 million???
5 studies of T-DM1 in combination with others- Unless I'm missing it, these aren't really good for IMGN.
Revs @ 6.9mil - 52% of street estimates? Revised guidance for full year down 15%? It just seems to get progressively worse with this company. I am glad I just have them on my watchlist...one dog in the portfolio is wreaking enough havoc. 400 shares sitting at $15.08 on the bid I am tempted to short but is already a 5% discount to yesterday's close. Guess I keep watching. Anyone care to suggest a reasonable bottom?
I don't look at the revenue on this one as it is all about the pipeline. Anything you can buy at this price or below you will be golden. The next 6-8 months there will be a ton of data coming out that will drive this over 20 IMO.
Sentiment: Strong Buy
Sounds like a guy who owns 20 shares, so certain. This report is a debacle. Survive it and then you'll be golden, lol. How come you're not lifting offers, goldenboy?
Relative disappointing things for today but still highly promising within 1 or 2 quarters
Sorry I own 2100 shares...and I stated that it was my opinion which you don't have to agree with.
Sentiment: Strong Buy
It's a good day to cover shorts, or buy, the quarter looked worse due to a 1-time charge. They should have reported an adjusted number. Revs were disappointing, progress is disappointing, but at this price, IMGN is a value biotech thanks to DJ's poor leadership. Not happy with the miss, but not panicking..